Vestal Point Capital’s OnKure Therapeutics OKUR Stock Holding History

Vestal Point Capital’s Portfolio OKUR Stock Details OKUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.62M	Buy	1,839,819 +1,204,819	+190%	+$3.72M	0.21%	69
2025 Q4	$1.84M	Hold	635,000	–	–	0.06%	71
2025 Q3	$1.75M	Hold	635,000	–	–	0.08%	77
2025 Q2	$1.52M	Hold	635,000	–	–	0.08%	64
2025 Q1	$2.73M	Hold	635,000	–	–	0.2%	50
2024 Q4	$5.46M	Buy	635,000 +555,060	+694%	+$8.4M	0.32%	52
2024 Q3	$1.36M	Buy	79,940 +25,440	+47%	+$376K	0.1%	66
2024 Q2	$823K	Buy	54,500 +24,962	+85%	+$423K	0.06%	59
2024 Q1	$490K	Sell	29,538 -10,462	-26%	-$173K	0.04%	56
2023 Q4	$640K	Buy	+40,000	New	+$2.49M	0.07%	41

Other funds holding OKUR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Vestal Point Capital's OKUR Position: Q1 2026 in Review

Vestal Point Capital increased its OnKure Therapeutics (OKUR) stake by 190% in Q1 2026, buying an estimated $3.72M and bringing the position to 1,839,819 shares worth $7.62M. The position accounts for 0.21% of the portfolio, ranked #69.

Vestal Point Capital first reported a position in OKUR in Q4 2023 and has held it in 10 quarters since. 51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

Vestal Point Capital held 1,839,819 shares of OnKure Therapeutics worth $7.62M as of Q1 2026.
Vestal Point Capital bought 1,204,819 OnKure Therapeutics shares in Q1 2026, an estimated $3.72M.
OnKure Therapeutics made up 0.21% of Vestal Point Capital's portfolio in Q1 2026, its #69 holding.
Vestal Point Capital first reported a position in OnKure Therapeutics in Q4 2023 and has held it in 10 quarters since.
51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.